These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 30707733

  • 1. Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.
    Ren S, Chen X, Wang Z, Zhao R, Wang J, Cui W, Wang Z.
    PLoS One; 2019; 14(2):e0211566. PubMed ID: 30707733
    [Abstract] [Full Text] [Related]

  • 2. Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.
    Karmazanovsky G, Belousova E, Schima W, Glotov A, Kalinin D, Kriger A.
    Eur J Radiol; 2019 Jan; 110():66-73. PubMed ID: 30599875
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.
    Reinert CP, Baumgartner K, Hepp T, Bitzer M, Horger M.
    Abdom Radiol (NY); 2020 Mar; 45(3):750-758. PubMed ID: 31953587
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.
    Chen HY, Pan Y, Chen JY, Liu LL, Yang YB, Li K, Yu RS, Shao GL.
    Eur Radiol; 2022 Dec; 32(12):8317-8325. PubMed ID: 35759016
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the "Duct-Road Sign": A preliminary magnetic resonance imaging study.
    Xiao B, Jiang ZQ, Hu JX, Zhang XM, Xu HB.
    Medicine (Baltimore); 2019 Aug; 98(35):e16960. PubMed ID: 31464937
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of texture analysis for grading pancreatic neuroendocrine tumors on contrast-enhanced computed tomography and apparent diffusion coefficient maps.
    Ohki K, Igarashi T, Ashida H, Takenaga S, Shiraishi M, Nozawa Y, Ojiri H.
    Jpn J Radiol; 2021 Jan; 39(1):66-75. PubMed ID: 32885378
    [Abstract] [Full Text] [Related]

  • 19. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.
    Belousova E, Karmazanovsky G, Kriger A, Kalinin D, Mannelli L, Glotov A, Karelskaya N, Paklina O, Kaldarov A.
    Clin Radiol; 2017 Feb; 72(2):150-158. PubMed ID: 27890421
    [Abstract] [Full Text] [Related]

  • 20. Differentiation of duodenal gastrointestinal stromal tumors from hypervascular pancreatic neuroendocrine tumors in the pancreatic head using contrast-enhanced computed tomography.
    Ren S, Chen X, Wang J, Zhao R, Song L, Li H, Wang Z.
    Abdom Radiol (NY); 2019 Mar; 44(3):867-876. PubMed ID: 30293109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.